Category: 227940-70-7

On April 30, 2008, Liu, Jie; Yang, Zhigang; Wang, Zhen; Wang, Fei; Chen, Xiaohong; Liu, Xiaohua; Feng, Xiaoming; Su, Zhishan; Hu, Changwei published an article.SDS of cas: 227940-70-7 The title of the article was Asymmetric Direct Aldol Reaction of Functionalized Ketones Catalyzed by Amine Organocatalysts Based on Bispidine. And the article contained the following:

Organocatalysts containing primary-secondary amine based on bispidine and amino acid have been designed to catalyze the asym. direct aldol reaction of functionalized ketones including α-keto phosphonates, α-keto esters, as well as α,α-dialkoxy ketones as aldol reaction acceptors. The corresponding products with chiral tertiary alcs. were obtained in moderate to high yields (up to 97%) and high enantioselectivities (up to 98% ee). A theor. study of transition structures demonstrated that protonated piperidine was important for the reactivity and enantioselectivity of this reaction. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).SDS of cas: 227940-70-7

The Article related to amino acid bispidine addition, aminobispidine preparation organocatalyst, ketone acetone butanone cyclohexanone direct aldol addition aminobispidine organocatalyst, alc asym preparation b3lyp hartree fock transition state structure and other aspects.SDS of cas: 227940-70-7

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On April 15, 2015, Yamashita, Hiroko; Demizu, Yosuke; Misawa, Takashi; Shoda, Takuji; Kurihara, Masaaki published an article.Application In Synthesis of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate The title of the article was Synthesis of a bis-cationic α,α-disubstituted amino acid (9-amino-bispidine-9-carboxylic acid) and its effects on the conformational properties of peptides. And the article contained the following:

A new bis-cationic cyclic amino acid, 9-amino-3,7-diazabicyclo[3.3.1]nonane-9-carboxylic acid (9-amino-bispidine-9-carboxylic acid = Abp), which is available for both solution phase and solid phase peptide synthesis, was designed and synthesized. Furthermore, a heterotripeptide Cbz-Leu-Abp-Ala-OMe containing Abp was prepared, and its dominant conformation was analyzed by examining its NMR and IR spectra and performing mol. modeling. The tripeptide Cbz-Leu-Abp-Ala-OMe formed a β-turn structure as its preferred conformation in solution The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).Application In Synthesis of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The Article related to peptide amino bispidine synthesis conformation nmr ir, amino acid disubstituted amino bispidine synthesis, piperidone cyclocondensation benzylamine paraformaldehyde hydantoin bucherer berg cyclization, hydrolysis protection peptide coupling conformation mol modeling and other aspects.Application In Synthesis of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On May 8, 2008, Shapiro, Gideon; Moncuso, John; Pierre, Tessier; Leit, Silvana; Deziel, Robert; David, Smil; Richard, Chesworth; Chantigny, Yves Andre; Patrick, Beaulieu published a patent.Safety of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate The title of the patent was Preparation of tricyclic hydroxamic acids as inhibitors of histone deacetylase. And the patent contained the following:

The title compounds I [Z = N(R1)OR2, H; L = a bond, N(OR2); when L = N(OR2), Z = H; when Z = H, L = N(OR2); R1, R2 = H, alkyl, aryl, etc.; J = a bond, :CH-, alkyl, alkyl(heteroalkyl)alkyl, etc.; Q = diazepine, pyrrolidine, diazabicyclo[3.3.1]nonane, etc.; B = dibenzo[b,f][1,4]oxazepine, benzo[b]pyrido[2,3-e][1,4]diazepine, benzo[f]thieno[2,3-b][1,4]oxazepine, etc.;], useful for the inhibition of histone deacetylase, were prepared E.g., a 3-step synthesis of II, starting from 10,11-dihydrodibenz[b,f][1,4]oxazepin-11-one, was given. All exemplified compounds I have an IC50 of ≤ 10 μM against one of more of HDAC-1 through HDAC-11 (data for representative compounds I were given). Pharmaceutical composition comprising the compound I and methods of treating polyglutamine (polyQ) expansion diseases such as Huntington’s disease, are disclosed. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).Safety of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The Article related to tricyclic hydroxamic acid preparation histone deacetylase hdac inhibitor, huntington’s disease treatment tricyclic hydroxamic acid preparation hdac inhibitor, dibenzoxazepine preparation histone deacetylase hdac inhibitor dentatorubralpallidoluysian atrophy treatment and other aspects.Safety of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On November 12, 2009, Rogers, Kathryn; Patzke, Holger published a patent.Reference of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate The title of the patent was Preparation of benzo-fused 7-membered heterocyclic compounds and methods for treating cognitive disorders using inhibitors of histone deacetylase. And the patent contained the following:

This disclosure relates to compounds for the inhibition of histone deacetylase and treatment of a cognitive disorder or deficit, more specifically neurodegenerative disease, polyglutamine disease, tauopathy, Alzheimer’s Disease, or Huntington’s Disease. More particularly, the disclosure provides for compounds of formula [I; Z = H, (un)substituted NHOH; L = a covalent bond, (un)substituted N(OH); when L = (un)substituted N(OH), Z = H; when Z = H, L = (un)substituted N(OH); J = a covalent bond, :CH, -C1-8 alkyl-, -C0-3 alkyl-C1-5 heteroalkyl-C0-3 alkyl-, -C0-3 alkyl-C2-5 alkenyl-C0-3 alkyl-, -C0-3 alkyl-C2-5 alkynyl-C0-3 alkyl-, -C0-6 alkylaryl-C0-6 alkyl-, -C0-6 alkylaryl-C2-6 heteroalkyl-, etc.; Q = heterocycle-containing group, a covalent bond, -C1-8 alkyl-, -C1-5 alkyl-, -C1-5 heterocyclyl-, ;N-O-, N-(un)substituted -C0-6 alkyl-NH-C0-3 alkyl-, -C0-6 alkyl-O-C0-3 alkyl-, etc.; ring B = 7-membered fused heterocycle group, etc.] or a pharmaceutically acceptable salts thereof. Thus, to a solution of (E)-1-chlorodibenzo[b,f][1,4]oxazepine (229 mg, 1.00 mmol) in DME (3 mL) was added 4-methoxycarbonylphenylboronic acid (216 mg), Pd(PPh3)4 (0.065 mg) and 2 N Na2CO3 (aqueous) (1.5 mL). The reaction mixture was stirred for 2 h at 90° to give, after workup and silica gel chromatog., (Z)-Me 4-(dibenzo[b,f][1,4]oxazepin-1-yl)benzoate (II) (327 mg, 99%) as a yellow foam. To a stirring solution of ester II (327 mg) in MeOH (4.0 mL) and THF (4.0 mL) was added 50% hydroxylamine (aqueous) (1.2 mL, excess) followed by KOH (212 mg) and the reaction mixture was stirred at room temperature for 15 min to give, after workup and silica gel chromatog., (Z)-4-(dibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide (III). III showed IC50 of ≤0.05 μM against histone deacetylase and also IC50 of ≤1 μM for whole-cell histone deacetylase (HDAC) Inhibition assay in primary mouse cortical cultures. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).Reference of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The Article related to benzo fused 7 membered heterocycle preparation histone deacetylase inhibitor, neurodegenerative disease polyglutamine disease treatment heterocycle preparation, tauopathy alzheimer disease huntington disease treatment heterocycle preparation, dibenzooxazepine benzopyridooxazepine dibenzothiazepine and other aspects.Reference of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On October 1, 2017, Bulygina, Ludmila A.; Kagramanov, Nikolay D.; Khrushcheva, Natalya S.; Lyssenko, Konstantin A.; Peregudov, Aleksander S.; Sokolov, Viacheslav I. published an article.Application of 227940-70-7 The title of the article was Unsymmetrical pincer CNN palladium complex of 7-ferrocenylmethyl-3-methyl-3,7-diazabicyclo[3.3.1]nonane. And the article contained the following:

The new unsym. ferrocenyl containing bispidine derivative 7 was synthesized as a ligand precursor in five steps starting from N-Boc-4-oxopiperidine. The corresponding palladium CNN pincer complex 8 was prepared by direct cyclopalladation of the ligand 7 with Li2PdCl4 in MeOH. The mol. structure of the obtained palladacycle was determined by multinuclear NMR (1H, 13C, 15N) and confirmed by x-ray diffraction anal. The pincer complex 8 demonstrated high catalytic activity in some cross-coupling reactions of aryl halides with phenylboronic acid, norbornene and Et acrylate. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).Application of 227940-70-7

The Article related to unsym pincer cnn palladium ferrocenylmethyldiazabicyclononane cyclometalated preparation crystal structure, crystal mol structure ferrocenylmethyldiazabicyclononane palladium cyclometalated complex, cross coupling heck hydroarylation norbornene ethyl acrylate catalyst preparation, suzuki coupling phenylboronic acid aryl halide catalyst preparation and other aspects.Application of 227940-70-7

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Roy, Arundhati; Saha, Debasis; Mandal, Prashant Sahebrao; Mukherjee, Arnab; Talukdar, Pinaki published an article in 2017, the title of the article was pH-Gated Chloride Transport by a Triazine-Based Tripodal Semicage.Related Products of 227940-70-7 And the article contains the following content:

Tris(diazabicyclo[3.3.1]octyl)triazines I (R = PhCH2, C6F5CH2, H) were prepared as ion transporters. The cation and anion transporting selectivities of I were determined; I (R = PhCH2, C6F5CH2) acted as efficient transmembrane Cl- carriers, while I (R = H) was too polar to effectively transport ions through membranes. I (R = PhCH2, C6F5CH2) functioned as mobile carriers for Cl- via an antiport exchange mechanism. Mol. dynamic simulations with I (R = PhCH2) show a strong Cl- binding within the cavity by direct and water-mediated hydrogen bonding. The structures of I were determined by X-ray crystallog. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).Related Products of 227940-70-7

The Article related to trisdiazabicyclononyltriazine preparation ion transporter, acid dependence anion cation selectivity transmembrane transport trisdiazabicyclononyltriazine, chloride selectivity transmembrane transport trisdiazabicyclononyltriazine, mol dynamics crystal structure trisdiazabicyclononyltriazine, antiport mechanism, chloride selectivity, preorganization and other aspects.Related Products of 227940-70-7

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On December 1, 2013, Eibl, Christoph; Munoz, Lenka; Tomassoli, Isabelle; Stokes, Clare; Papke, Roger L.; Guendisch, Daniela published an article.Computed Properties of 227940-70-7 The title of the article was The 3,7-diazabicyclo[3.3.1]nonane scaffold for subtype selective nicotinic acetylcholine receptor ligands. Part 2: Carboxamide derivatives with different spacer motifs. And the article contained the following:

3,7-Diazabicyclo[3.3.1]nonane (bispidine) based nicotinic acetylcholine receptor (nAChR) ligands, e.g., I, have been synthesized and evaluated for nAChRs interaction. Diverse spacer motifs were incorporated between the hydrogen bond acceptor (HBA) part and a variety of substituted (hetero)aryl moieties. Bispidine carboxamides bearing spacer motifs often showed high affinity in the low nanomolar range and selectivity for the α4β2* nAChR. Compound I and the other two tested compounds with Ki values of about 1 nM displayed the highest affinities for α4β2* nAChR. All evaluated compounds are partial agonists or antagonists at α4β2*, with reduced or no effects on α3β4* with the exception of compound I (agonist), and reduced or no effect at α7 and muscle subtypes. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).Computed Properties of 227940-70-7

The Article related to brain disease, central nervous system agents, central nervous system disease, laburnum anagyroides (seeds and pods), mathematical methods (acd/adme and acd/physchem), nicotinic agonists, nicotinic antagonists, structure-activity relationship and other aspects.Computed Properties of 227940-70-7

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On December 1, 2013, Eibl, Christoph; Tomassoli, Isabelle; Munoz, Lenka; Stokes, Clare; Papke, Roger L.; Guendisch, Daniela published an article.Recommanded Product: tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate The title of the article was The 3,7-diazabicyclo[3.3.1]nonane scaffold for subtype selective nicotinic acetylcholine receptor (nAChR) ligands. Part 1: The influence of different hydrogen bond acceptor systems on alkyl and (hetero)aryl substituents. And the article contained the following:

3,7-Diazabicyclo[3.3.1]nonane is a naturally occurring scaffold interacting with nicotinic acetylcholine receptors (nAChRs). When one nitrogen of the 3,7-diazabicyclo[3.3.1]nonane scaffold was implemented in a carboxamide motif displaying a hydrogen bond acceptor (HBA) functionality, compounds with higher affinities and subtype selectivity for α4β2* were obtained. The nature of the HBA system (carboxamide, sulfonamide, urea) had a strong impact on nAChR interaction. High affinity ligands for α4β2* possessed small alkyl chains, small un-substituted hetero-aryl groups or para-substituted Ph ring systems along with a carboxamide group. Electrophysiol. responses of selected 3,7-diazabicyclo[3.3.1]nonane derivatives to Xenopus oocytes expressing various nAChR subtypes showed diverse activation profiles. Compounds with strongest agonistic profiles were obtained with small alkyl groups whereas a shift to partial agonism/antagonism was observed for aryl substituents. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).Recommanded Product: tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The Article related to blood-brain barrier, brain, drug transport, homo sapiens, human, lipophilicity, nicotinic receptors role: bsu (biological study, unclassified), biol (biological study), structure-activity relationship, nicotinic receptor-binding and other aspects.Recommanded Product: tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics